Table 7.
Association between duration of treatment and treatment success by MDR-TB patient group
| 7a. Duration of intensive phase | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of intensive phase (months) | MDR-TB, susceptible to FQ & INJ (“MDR-TB only”) | MDR-TB+INJr | MDR-TB+FQr | XDR-TB | ||||||||
| N | aOR | (95%CI) | N | aOR | (95%CI) | N | aOR | (95%CI) | N | aOR | (95%CI) | |
| 1 – 4.0 | 1924 | 1.0 | (reference) | 99 | 1.0 | (reference) | 33 | 1.0 | (reference) | 55 | 1.0 | (reference) |
| 4.1 – 6.5 | 274 | 2.8 | (0.8, 9.7) | 82 | 3.2 | (0.8, 13.6) | 41 | 0.9 | (0.2, 4.5) | 41 | 6.1 | (0.6, 62) |
| 6.6 – 9.0 | 244 | 3.1 | (1.1, 8.3) | 79 | 9.8 | (1.9, 49) | 36 | 0.6 | (0.1, 4.1) | 37 | 71.0 | (5.2, 200) |
| 9.1 – 20.0 | 347 | 2.1 | (0.9, 5.1) | 155 | 4.1 | (1.5, 11.2) | 55 | 0.4 | (0.1, 2.0) | 77 | 5.1 | (1.2, 21) |
| 7b. Total duration of treatment | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total duration of treatment (months) | MDR-TB, susceptible to FQ & INJ (“MDR-TB only”) | MDR-TB+INJr | MDR-TB+FQr | XDR-TB | ||||||||
| N | aOR | (95%CI) | N | aOR | (95%CI) | N | aOR | (95%CI) | N | aOR | (95%CI) | |
| 6.0 – 15.0 | 443 | 1.0 | (reference) | 279 | 1.0 | (reference) | 54 | 1.0 | (reference) | 87 | 1.0 | (reference) |
| 15.1 – 20.0 | 2171 | 3.6 | (1.7, 7.9) | 260 | 3.1 | (1.0, 9.1) | 47 | 2.4 | (0.4, 14.3) | 79 | 2.0 | (0.3,11.7) |
| 20.1 – 25.0 | 484 | 5.9 | (3.0, 11.5) | 202 | 7.7 | (3.8,15.7) | 60 | 2.1 | (0.7, 6.5) | 61 | 5.5 | (1.7, 17.6) |
| 25.1 – 30.0 | 147 | 2.8 | (1.2, 6.9) | 65 | 6.0 | (2.3,15.6) | 24 | 4.1 | (0.9, 19.4) | 21 | 5.8 | (1.3, 25.1) |
| 30.1 – 36.0 | 61 | 1.8 | (0.6, 5.6) | 17 | 2.9 | (0.7,12.2) | 13 | 1.1 | (0.2, 5.2) | 10 | 1.3 | (0.2, 7.8) |
MDR-TB = resistance to at least isoniazid and rifampicin
XDR-TB = MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug (amikacin/kanamycin and/or capreomycin)
MDR-TB+FQr = MDR-TB plus resistance to any fluoroquinolone, but susceptible to amikacin/kanamycin and/or capreomycin (at least one second-line injectable drug tested)
MDR-TB+INJr = MDR-TB plus resistance to amikacin/kanamycin and/or capreomycin, but susceptible to fluoroquinolones
MDR-TB, susceptible to FQ & INJ = MDR-TB, but susceptible to fluoroquinolones, amikacin/kanamycin and capreomycin (at least one second-line injectable drug tested)
N: Number of cases
aOR (adjusted odds ratios): odds ratios of treatment success versus treatment failure or relapse adjusted for age, sex, HIV infection, previous TB treatment, previous MDR treatment (treatment for more than 1 month with two or more second line drugs), and extent of disease. See Methods and Laserson et al (2005) for treatment outcome definitions
CI = confidence intervals
Intensive phase: is the initial part of a course of treatment during which an injectable drug is given. Continuation phase: is the period immediately following the initial phase when no injectable drug is given.